How long can capmatinib (Touradida) prolong the survival of advanced patients?

Capmatinib (capmatinib) is a selective MET inhibitor, mainly used to treat patients with non-small cell lung cancer who have MET exon 14 skipping mutations. In clinical studies, the drug has shown higher objective response rates and longer-lasting disease control in both first- and second-line treatment populations. For advanced patients, capmatinib can not only reduce tumor size, but also significantly extend progression-free survival, giving them more treatment and life time.

Based onGEOMETRY According to data from the mono-1 study, the median progression-free survival of MET mutation-positive patients who have not received systemic treatment after capmatinib is approximately 12.4 months, while the progression-free survival of patients who have received previous treatment can also reach about 5.4 months. More importantly, some patients have significantly reduced tumor burden during treatment, and even experienced disease remission that lasted for more than a year, which is of great significance for improving the quality of life of advanced patients.

In terms of overall survival, although there are certain differences between different studies, data show that capmatinib can provide a median overall survival of approximately 20 months for advanced patients, which is significantly better than traditional chemotherapy regimens. Especially in first-line treatment, patient benefits are more prominent, and the survival time of some individual patients even exceeds two years, which reflects the value of targeted drugs in precision medicine. The survival benefit may be longer for patients who develop resistance more slowly or whose resistance mechanisms are controllable.

It needs to be emphasized that the efficacy and survival prolongation of capmatinib are closely related to the patient's gene mutation status, overall physical condition, and whether side effects are monitored and dealt with in a timely manner. For patients with advanced non-small cell lung cancer, rational selection of capmatinib, strict compliance with physician guidance, and regular imaging and molecular testing can help maximize survival time. At the same time, with the advancement of research on new generations of MET inhibitors and combination treatment strategies, the survival of patients is expected to be further improved in the future.

Reference materials:https://www.drugs.com/